AXSM News and Press, Axsome Therapeutics Inc. From 11/06/23

Axsome Therapeutics Inc. (AXSM) is expected to report $-1.24 for Q3 2023

2023-11-03 11:17:30 ET More on Axsome Therapeutics Axsome Update: Buy At Dips And Hold Forever Axsome: Beyond The Numbers - Q2 Earnings Sparkle And A Pipeline Full Of Promise Axsome Therapeutics, Inc. (AXSM) Q2 2023 Earnings Call Transcript Mizuho says market...

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it is joining advocacy organizations around the world to help r...

NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced a presentation of data from its ACCORD Phase 3 clinical trial o...

2023-10-23 05:30:00 ET Even though the stock market has rallied since the start of the year, with the S&P 500 and the Nasdaq rising by double-digit percentages, some stocks haven't benefited from the positive momentum. And among these stragglers, you might find great deals. Cert...

2023-10-16 06:11:56 ET Summary Axsome Therapeutics' Auvelity is experiencing strong sales growth in the Major Depressive Disorder space, with sales of $27.6 million in the last quarter. Auvelity offers rapid onset of symptom improvement, providing swift relief for patients seeking...

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Susan Mahony, PhD, has been appointed to Axsome’s b...

NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter...

2023-10-04 12:32:07 ET More on Harmony Biosciences Harmony Biosciences: A Balancing Act As Investors Lose Some Sleep Harmony Biosciences Holdings, Inc. 2023 Q2 - Results - Earnings Call Presentation Harmony Biosciences Holdings, Inc. (HRMY) Q2 2023 Earnings Call Tran...

2023-10-03 05:30:00 ET Biotech stocks offer us a wide range of investing opportunities. You could buy shares of a research stage company and bet on a potential game-changing product that may launch several years from now. Or you could invest in commercial stage companies that might be about...